| 28.56 0 (0%) | 07-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 54.83 | 1-year : | 64.05 |
| Resists | First : | 46.95 | Second : | 54.83 |
| Pivot price | 7.03 |
|||
| Supports | First : | 18.14 | Second : | 0.34 |
| MAs | MA(5) : | 20.23 |
MA(20) : | 5.37 |
| MA(100) : | 1.36 |
MA(250) : | 0.69 |
|
| MACD | MACD : | 5.9 |
Signal : | 2.4 |
| %K %D | K(14,3) : | 70.9 |
D(3) : | 63.7 |
| RSI | RSI(14): 68.7 |
|||
| 52-week | High : | 46.95 | Low : | 0.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VYNE ] has closed below upper band by 11.0%. Bollinger Bands are 3449.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 28.75 - 28.87 | 28.87 - 28.96 |
| Low: | 23.11 - 23.22 | 23.22 - 23.33 |
| Close: | 28.32 - 28.55 | 28.55 - 28.74 |
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Fri, 11 Sep 2026
Vyne Therapeutics Inc (NASDAQ: VYNE) Share Price, VYNE Stock News, VYNE Share Price & Updates - Kalkine
Wed, 29 Jul 2026
YARW - Yarrow Bioscience Inc Stock Price and Quote - Finviz
Mon, 27 Jul 2026
Yarrow Bioscience Completes VYNE Merger and $200 Million Private Financing - citybiz.co
Fri, 24 Jul 2026
VYNE Therapeutics (VYNE) CLO has shares withheld for RSU taxes - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 613690 (%) |
| Held by Institutions | 17.9 (%) |
| Shares Short | 2 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.434e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 437.2 % |
| Return on Equity (ttm) | -37.1 % |
| Qtrly Rev. Growth | 454000 % |
| Gross Profit (p.s.) | -28.56 |
| Sales Per Share | -31.43 |
| EBITDA (p.s.) | 225871 |
| Qtrly Earnings Growth | -27.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.91 |
| Price to Cash Flow | 1.55 |
| Dividend | 0 |
| Forward Dividend | 3680 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2000-12-20 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|